Expanding Oncology Pipeline to Three Novel Molecules Following its Series A+ Financing Round

HANGZHOU, China and NEW YORK, Sept. 07, 2020 (GLOBE NEWSWIRE) — AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, has through its subsidiary AnHeart Therapeutics Inc. entered into license agreements with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”, TYO:4568) to acquire rights to two novel clinical stage oncology candidates (previously Daiichi Sankyo codes DS-1001 and DS-1205, now AnHeart codes AB-218 and AB-329, respectively). Under the terms of the agreements, Daiichi Sankyo is eligible to receive upfront payments, as well as development, regulatory and commercial milestone payments and royalties on net sales following market approval of the products.

AB-218 is a novel, potent, highly selective mutant IDH-1 inhibitor, which has high permeability of the blood-brain barrier and has demonstrated encouraging safety and efficacy signals in a Phase 1